⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RVMD News
Revolution Medicines, Inc. Common Stock
Capture More Revenue Without Adding Patients Using RevolutionEHR’s Dr. Contact Lens Integration
businesswire.com
RVMD
PRCT
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
globenewswire.com
RVMD
Form 8-K
sec.gov
RVMD
RVMDW
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
globenewswire.com
RVMD
Form 8-K
sec.gov
RVMD
RVMDW
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
globenewswire.com
RVMD
Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes
globenewswire.com
RVMD
Form 8-K
sec.gov
RPRX
RVMD
Form 8-K
sec.gov
RVMDW
RVMD
Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
globenewswire.com
RVMD